Publication|Articles|September 18, 2025
Supplements and Featured Publications
- Effectiveness and Safety of Arimoclomol for the Treatment of Neurological Manifestations of Niemann-Pick Disease Type C: A Review of Clinical Trial Data
Effectiveness and Safety of Arimoclomol for the Treatment of Neurological Manifestations of Niemann-Pick Disease Type C: A Review of Clinical Trial Data
Key Takeaways
- Zevra Therapeutics emphasizes innovative treatments and emerging technologies in oncology to improve patient outcomes.
- Collaboration between pharmaceutical companies and healthcare professionals is crucial for accelerating effective cancer therapy development.
Advertisement
This clinical brief is sponsored by Zevra Therapeutics.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
2
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
3
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
4
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
5









































